Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levetiracetam, Keppra Clear all
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

NCT00141115
View directory record Official record
Conditions
Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia, Anxiety Disorders
Interventions
levetiracetam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
levetiracetam, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR (Levetiracetam XR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 8, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

NCT00862563
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 8, 2026, 5:49 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Withdrawn Phase 2 Interventional

Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study

NCT00627133
View directory record Official record
Conditions
Seizure, Alcohol Related
Interventions
levetiracetam
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Established Status Epilepticus Treatment Trial

NCT01960075
View directory record Official record
Conditions
Benzodiazepine Refractory Status Epilepticus
Interventions
Fosphenytoin, Levetiracetam, Valproic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
2 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
65
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Levetiracetam 1000 mg Under Non-Fasting Conditions

NCT00859430
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam, Keppra®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 8, 2026, 5:49 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 8, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
View directory record Official record
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Levetiracetam Treatment of L-dopa Induced Dyskinesias

NCT00076674
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
Intravenous Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 8, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

NCT05610085
View directory record Official record
Conditions
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions
Levetiracetam Injection, Phenobarbital Sodium Injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 1 Month
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Recruiting Phase 4 Interventional

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

NCT06866691
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
levetiracetam, lacosamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

NCT00489281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 8, 2026, 5:49 PM EDT
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 5:49 PM EDT
Terminated No phase listed Observational

Efficacy of Keppra for Neonatal Seizures

NCT01475656
View directory record Official record
Conditions
Neonatal Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Stephanie Merhar, MD
Other
Eligibility
Up to 30 Days
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Levetiracetam for Treatment of Pain Associated With Fibromyalgia

NCT00254657
View directory record Official record
Conditions
Fibromyalgia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

NCT00203216
View directory record Official record
Conditions
Migraine
Interventions
levetiracetam, Transcranial Magnetic Stimulation
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Not applicable Interventional

A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy

NCT00361010
View directory record Official record
Conditions
Epilepsy, Childhood Absence Epilepsy, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

NCT00279617
View directory record Official record
Conditions
Panic Disorder
Interventions
levetiracetam
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Oct 8, 2026, 5:49 PM EDT
Completed Phase 4 Interventional

Levetiracetam for Benign Rolandic Epilepsy

NCT00181116
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 8, 2026, 5:49 PM EDT